-
Qiming Medical's TriGUARD3 Chinese registered clinical trial successfully completed the first case enrollment
Time of Update: 2021-07-07
TriGUARD3TM completely covers the innominate artery of the aortic branch, the left carotid artery and the subclavian artery openings, which can reduce embolic materials entering the brain, thereby minimizing the risk of brain damage during transcatheter aortic valve replacement (TAVR) surgery , Fully protect the brain tissue .
-
WuXi AppTec's growth rate in the first quarter of 2021 hits a record high
Time of Update: 2021-07-07
, a company capable of providing comprehensive and integrated new drug R&D and production services and technology platform for the global biomedical industry, released the first quarter report of 2021 .
-
If you want to make a breakthrough in the PD-1 market under the trend of low prices, Fosun has only this set of "seven injuries"!
Time of Update: 2021-07-07
At the same time, if the drug is launched in China, it will undoubtedly become the target of many PD-1 producers, and it is still unclear whether it can be approved for MSI-H solid tumors of all diseases, and there is a high probability that it will be selective in high-incidence diseases.
-
Aimike, which only sells hyaluronic acid, has doubled its profit and income in the first quarter.
Time of Update: 2021-07-07
According to its 2021 annual report, this type of product achieved operating income of 450 million yuan, an increase of 82.
According to its annual report, gel injection products will reach 252 million yuan in 2020, accounting for 35.
-
Renfu Medicine's midazolam oral solution was approved
Time of Update: 2021-07-07
, a subsidiary of the company, has recently received the "Drug Registration Certificate" for midazolam oral solution approved and issued by the State Drug Administration .
-
The new crown vaccine revenue is expected to be comparable to the annual revenue, and the expansion of the production and sales of independent products is a trend
Time of Update: 2021-07-07
The cumulative number of HPV vaccines issued exceeds 25 million doses, and the introduction of imported products And promotion, greatly increased the company's revenue and profits .
-
Leading Biotech and Baitu Biotech reached ecological cooperation
Time of Update: 2021-07-07
As the first biocomputing-driven life science platform company in China, we are very pleased to reach an all-round ecological cooperation with Leadstar Bio, using AI and computing's data mining capabilities to jointly promote the clinical progress and scientific research transformation of innovative drugs .
-
Rongchang, Lepu, and Kelun are enthusiastic about research and development.
Time of Update: 2021-07-07
ADC drugs combine the high specificity of monoclonal antibody drugs with the high activity of small molecule cytotoxic drugs to improve the targeting of tumor drugs and reduce toxic side effects .
-
The TOP list of pharmaceutical companies' R&D investment is released!
Time of Update: 2021-07-07
The BCMA-targeted CAR-T therapy jointly developed by Johnson & Johnson and Legend Bio has completed the submission of a regulatory application to the US FDA and is expected to be approved this year .
-
Philips releases the Chinese version of the 2020 annual report, achieving steady growth in its annual performance
Time of Update: 2021-07-07
9 billion euros, order absorption created a 9% increase, and its market share was improved in some business aspects in the health and medical field .
-
WuXi Biologics completes 3 simultaneous acquisitions and continues to increase production capacity and scale
Time of Update: 2021-07-07
According to the agreement signed with Pfizer China in March 2021, WuXi Biologics has formally taken over the production bases of Hangzhou stock solution (MFG20) and preparations (DP9 and DP10), adding 2x2000 liters of stock solution and preparations (cillin bottles and prefilled needles) production capacity.
-
Amgen's new drug has been recognized by the FDA as a breakthrough therapy!
Time of Update: 2021-07-07
On April 19, 2021, Amgen announced that the FDA granted its research FGFR2b antibody therapy bemarituzumab breakthrough therapy designation, combined with chemotherapy, for the first-line treatment of HER2-negative locally advanced or metastatic gastric cancer and gastroesophagus Patients with cancer of the junction (GEJ) .
-
The actual controller of Zhifei Biological and its concordant reduce the company's shares by more than 1%
Time of Update: 2021-07-07
On the evening of April 26, Jiang Rensheng, the actual controller of Zhifei Biology, and Jiang Xisheng, the person acting in concert, reduced their holdings of 16.
0%, and net profit attributable to the parent company was 940 million yuan, a year-on-year increase of 81.
-
The first review!
Time of Update: 2021-07-07
On May 10, Enhua Pharmaceuticals issued an announcement stating that it had recently received the "Drug Supplementary Application Approval Notice" for "clonazepam tablets" approved and issued by the State Food and Drug Administration, and approved the drug to pass the quality and quality of generic drugs.
Up to now, the company's clonazepam tablets are the first domestic product to pass the consistency evaluation.
-
The first hyaluronic acid used for the back of the nose and the root of the nose is here, and several major medical and beauty giants are also aiming here
Time of Update: 2021-07-07
Reporter | Zheng JieEdit | Xie Xin On April 28th, Gao Demei announced that its injection-filled hyaluronic acid product Relan·Rixuan (hereinafter referred to as "Rixuan") was approved for the first domestic indication for nasal back and/or nose root shaping.
-
Dapagliflozin approved for chronic kidney disease indications in the U.S.
Time of Update: 2021-07-07
AstraZeneca announced that Anda Tang (generic name: dapagliflozin, sodium-glucose cotransporter-2 (SGLT2) inhibitor) was officially approved in the United States for the treatment of chronic kidney disease (CKD) that is at risk of disease progression In adult patients, it can reduce the associated risks including continuous decline in estimated glomerular filtration rate (eGFR), progression to end-stage renal disease (ESKD), cardiovascular (CV) death, and heart failure hospitalization (hHF) .
-
Zhou Jie, director and general manager of First Pharmaceutical, resigns
Time of Update: 2021-07-07
Due to personal reasons, Zhou Jie requested to resign as a director of the company's ninth board of directors, a member of the strategic committee of the board of directors and the general manager .
After resignation, Zhou Jie no longer holds any position in the company .
-
An enterprise in Jilin Province was reported and fined 113,000
Time of Update: 2021-07-07
The Food and Drug Administration finally imposed the following penalties on the company: Confiscated 77,800 medical surgical masks that did not meet the requirements of mandatory industry standards; fined 5 times the value of the goods totaling RMB 113,850 .
-
Shanggao Company Announces Appointment of New CEO
Time of Update: 2021-07-07
Yang has served as a partner of Wuhan Sinopharm Optics Valley Capital Management Co.
Yang Ou to join us as CEO at an important juncture in the transformation of Shanggao ’s main industries.
-
Zhongchao Medical releases financial results for fiscal year 2020
Time of Update: 2021-07-07
Zhongchao Medical (NASDAQ transaction code: ZCMD) (referred to as "Zhongchao Medical" or "Company"), a company dedicated to providing online healthcare information, professional medical training and education services for Chinese medical workers and the general public, in Today announced its financial results for the fiscal year ending December 31, 2020 .
